Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:DERM
- CUSIP: N/A
- Web: www.dermira.com
Capitalization:- Market Cap: $974.07 million
- Outstanding Shares: 41,591,000
Average Prices:- 50 Day Moving Avg: $27.10
- 200 Day Moving Avg: $30.50
- 52 Week Range: $21.35 - $38.75
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.46
- P/E Growth: -0.05
Sales & Book Value:- Annual Revenue: $24.72 million
- Price / Sales: 38.58
- Book Value: $8.95 per share
- Price / Book: 2.56
Profitability:- EBIDTA: ($102,210,000.00)
- Net Margins: -408.50%
- Return on Equity: -31.66%
- Return on Assets: -22.59%
Debt:- Debt-to-Equity Ratio: 0.75%
- Current Ratio: 24.43%
- Quick Ratio: 24.43%
Misc:- Average Volume: 453,020 shs.
- Beta: 0.8
- Short Ratio: 16.84
Frequently Asked Questions for Dermira (NASDAQ:DERM)
What is Dermira's stock symbol?
Dermira trades on the NASDAQ under the ticker symbol "DERM."
How were Dermira's earnings last quarter?
Dermira, Inc. (NASDAQ:DERM) announced its earnings results on Monday, August, 7th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.89) by $0.04. The business had revenue of $1.07 million for the quarter, compared to the consensus estimate of $1 million. Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. View Dermira's Earnings History.
Where is Dermira's stock going? Where will Dermira's stock price be in 2017?
9 brokerages have issued twelve-month price targets for Dermira's stock. Their predictions range from $40.00 to $48.00. On average, they expect Dermira's stock price to reach $43.80 in the next year. View Analyst Ratings for Dermira.
What are analysts saying about Dermira stock?
Here are some recent quotes from research analysts about Dermira stock:
- 1. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (8/17/2017)
- 2. Guggenheim analysts commented, "4Q16 results underscore that DERM continues to advance its pipeline of drugs that address large unmet needs in dermatology. Positive clinical data for DRM01 and DRM04 as well as solid execution in 4Q16, give us greater conviction in our positive investment thesis for the stock. We continue to think stock price appreciation will be driven by upward consensus earnings revisions to DERM's pipeline drug sales. We also view DERM as an attractive company in a consolidating industry." (3/2/2017)
Who are some of Dermira's key competitors?
Some companies that are related to Dermira include Loxo Oncology (LOXO), NovoCure Limited (NVCR), Halozyme Therapeutics (HALO), Radius Health (RDUS), Lexicon Pharmaceuticals (LXRX), Array BioPharma (ARRY), MyoKardia (MYOK), Acceleron Pharma (XLRN), Clinigen Group PLC (CLIN), Forward Pharma A/S (FWP), Omeros Corporation (OMER), Acorda Therapeutics (ACOR), NeuroDerm (NDRM), Dynavax Technologies Corporation (DVAX), Xencor (XNCR), Ascendis Pharma A/S (ASND), Retrophin (RTRX) and Sangamo Therapeutics (SGMO).
Who are Dermira's key executives?
Dermira's management team includes the folowing people:
- Thomas G. Wiggans, Chairman of the Board, Chief Executive Officer, Co-Founder
- Christopher M. Griffith, Senior Vice President - Corporate Development and Strategy, Founder
- Luis C. Pena, Co-Founder, Chief Development Officer
- Andrew L. Guggenhime, Chief Financial Officer, Chief Operating Officer
- Lori Lyons-Williams, Chief Commercial Officer
- Eugene A. Bauer M.D., Founder, Chief Medical Officer, Director
- Frederick B. Craves Ph.D., Lead Independent Director
- Emmanuel Caeymaex, Director
- David E. Cohen M.D., Independent Director
- Matthew K. Fust, Independent Director
Who owns Dermira stock?
Dermira's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.45%), NEA Management Company LLC (8.45%), FMR LLC (6.55%), Jennison Associates LLC (6.34%), TimesSquare Capital Management LLC (6.09%) and Vanguard Group Inc. (3.37%). Company insiders that own Dermira stock include Andrew Guggenhime, Christopher M Griffith, Eugene A Bauer, Fred B Craves, Luis C Pena, Thomas G Wiggans and William R Ringo. View Institutional Ownership Trends for Dermira.
Who sold Dermira stock? Who is selling Dermira stock?
Dermira's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Balyasny Asset Management LLC, Teachers Advisors LLC, TimesSquare Capital Management LLC, Wells Fargo & Company MN, Bank of New York Mellon Corp, TIAA CREF Investment Management LLC and Century Capital Management LLC. Company insiders that have sold Dermira stock in the last year include Andrew Guggenhime, Christopher M Griffith, Eugene A Bauer, Thomas G Wiggans and William R Ringo. View Insider Buying and Selling for Dermira.
Who bought Dermira stock? Who is buying Dermira stock?
Dermira's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Voya Investment Management LLC, Jennison Associates LLC, State Street Corp, Tekla Capital Management LLC, JPMorgan Chase & Co., Vanguard Group Inc. and Nexthera Capital LP. View Insider Buying and Selling for Dermira.
How do I buy Dermira stock?
Shares of Dermira can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dermira's stock price today?
One share of Dermira stock can currently be purchased for approximately $22.93.
MarketBeat Community Rating for Dermira (NASDAQ DERM)MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Dermira (NASDAQ:DERM) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Sell Ratings, 6 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.33) |
| Consensus Price Target: | $43.80 (91.02% upside) |
Analysts' Ratings History for Dermira (NASDAQ:DERM)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/18/2017 | Needham & Company LLC | Reiterated Rating | Buy | $46.00 | Low |  |
| 6/29/2017 | Evercore ISI | Initiated Coverage | Outperform | $48.00 | Medium | |
| 6/22/2017 | Cantor Fitzgerald | Initiated Coverage | Overweight | $45.00 | Medium | |
| 5/25/2017 | Mizuho | Lower Price Target | Buy -> Buy | $42.00 -> $40.00 | Low | |
| 3/16/2017 | Raymond James Financial, Inc. | Initiated Coverage | Underperform -> Underperform | | High | |
| 3/15/2017 | Citigroup Inc. | Initiated Coverage | Underperform | | High | |
| 3/2/2017 | Guggenheim | Reiterated Rating | Buy -> Positive | $40.00 | N/A | |
| 1/3/2017 | SEB Equity Research | Reiterated Rating | Reduce | | N/A | |
| 10/5/2016 | Leerink Swann | Reiterated Rating | Buy | | N/A | |
| 6/2/2016 | Wedbush | Boost Price Target | Outperform | $42.00 -> $46.00 | N/A | |
| 8/19/2015 | Cowen and Company | Initiated Coverage | Outperform | $40.00 | N/A | |
(Data available from 8/19/2015 forward)
Earnings History for Dermira (NASDAQ:DERM)Earnings History by Quarter for Dermira (NASDAQ DERM)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/7/2017 | Q2 2017 | ($0.89) | ($0.93) | $1.00 million | $1.07 million | View | N/A | |
| 2/28/2017 | Q4 2016 | ($0.93) | ($0.21) | | $22.47 million | View | Listen | |
| 11/7/2016 | Q316 | ($0.72) | ($0.72) | | $0.12 million | View | N/A | |
| 8/8/2016 | Q2 | ($0.86) | ($0.89) | | | View | N/A | |
| 5/10/2016 | Q1 | ($0.94) | ($0.95) | | | View | Listen | |
| 11/10/2015 | Q3 | ($0.77) | ($0.58) | | $7.30 million | View | N/A | |
| 8/13/2015 | Q2 | ($0.81) | ($0.69) | | | View | N/A | |
| 5/12/2015 | Q1 | ($0.65) | ($0.57) | | | View | N/A | |
| 3/25/2015 | Q4 | ($0.59) | ($0.29) | | $7.30 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Dermira (NASDAQ:DERM)2017 EPS Consensus Estimate: ($3.97)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.84) | ($0.84) | ($0.84) |
| Q2 2017 | 1 | ($0.81) | ($0.81) | ($0.81) |
| Q3 2017 | 1 | ($1.03) | ($1.03) | ($1.03) |
| Q4 2017 | 1 | ($1.29) | ($1.29) | ($1.29) |
(Data provided by Zacks Investment Research)
Dividend History for Dermira (NASDAQ:DERM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Dermira (NASDAQ:DERM)Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 83.82%
Insider Trades by Quarter for Dermira (NASDAQ:DERM)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/14/2017 | Fred B Craves | Director | Buy | 30,000 | $23.03 | $690,900.00 | |
| 8/1/2017 | Thomas G. Wiggans | CEO | Sell | 500 | $27.58 | $13,790.00 | |
| 7/5/2017 | Eugene A Bauer | Insider | Sell | 2,500 | $30.00 | $75,000.00 | |
| 7/3/2017 | Thomas G. Wiggans | CEO | Sell | 5,000 | $29.06 | $145,300.00 | |
| 6/20/2017 | Eugene A Bauer | Insider | Sell | 2,500 | $30.01 | $75,025.00 | |
| 6/2/2017 | Thomas G. Wiggans | CEO | Sell | 5,000 | $27.52 | $137,600.00 | |
| 5/15/2017 | Christopher M. Griffith | SVP | Sell | 1,312 | $27.07 | $35,515.84 | |
| 4/17/2017 | Christopher M. Griffith | SVP | Sell | 1,303 | $33.97 | $44,262.91 | |
| 4/3/2017 | Eugene A Bauer | Insider | Sell | 2,500 | $33.53 | $83,825.00 | |
| 4/3/2017 | Thomas G Wiggans | CEO | Sell | 8,000 | $33.49 | $267,920.00 | |
| 4/3/2017 | William R Ringo | Director | Sell | 500 | $34.03 | $17,015.00 | |
| 3/15/2017 | Christopher M. Griffith | SVP | Sell | 1,303 | $35.79 | $46,634.37 | |
| 3/1/2017 | Eugene A Bauer | Insider | Sell | 2,500 | $33.61 | $84,025.00 | |
| 3/1/2017 | Thomas G Wiggans | CEO | Sell | 11,000 | $33.54 | $368,940.00 | |
| 3/1/2017 | William R Ringo | Director | Sell | 500 | $35.09 | $17,545.00 | |
| 2/15/2017 | Christopher M. Griffith | SVP | Sell | 1,303 | $30.79 | $40,119.37 | |
| 2/15/2017 | William R Ringo | Director | Sell | 500 | $32.00 | $16,000.00 | |
| 2/14/2017 | Eugene A Bauer | Insider | Sell | 1,505 | $30.00 | $45,150.00 | |
| 2/1/2017 | Eugene A Bauer | Insider | Sell | 995 | $30.00 | $29,850.00 | |
| 1/17/2017 | Christopher M. Griffith | VP | Sell | 1,303 | $29.11 | $37,930.33 | |
| 1/4/2017 | Thomas G Wiggans | CEO | Sell | 8,000 | $31.06 | $248,480.00 | |
| 1/4/2017 | William R Ringo | Director | Sell | 500 | $32.00 | $16,000.00 | |
| 1/3/2017 | Eugene A Bauer | Insider | Sell | 2,500 | $30.07 | $75,175.00 | |
| 12/16/2016 | William R Ringo | Director | Sell | 125 | $32.00 | $4,000.00 | |
| 12/15/2016 | Christopher M. Griffith | VP | Sell | 1,303 | $30.70 | $40,002.10 | |
| 12/14/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $30.36 | $75,900.00 | |
| 12/1/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $30.80 | $338,800.00 | |
| 12/1/2016 | William R Ringo | Director | Sell | 375 | $32.00 | $12,000.00 | |
| 11/9/2016 | Andrew Guggenhime | CFO | Sell | 4,100 | $35.02 | $143,582.00 | |
| 11/9/2016 | William R Ringo | Director | Sell | 500 | $32.30 | $16,150.00 | |
| 11/1/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $31.19 | $343,090.00 | |
| 10/17/2016 | Christopher M Griffith | VP | Sell | 1,303 | $32.33 | $42,125.99 | |
| 10/11/2016 | Andrew Guggenhime | CFO | Sell | 10,900 | $34.34 | $374,306.00 | |
| 10/3/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $34.60 | $380,600.00 | |
| 10/3/2016 | William R Ringo | Director | Sell | 500 | $34.25 | $17,125.00 | |
| 9/19/2016 | Andrew Guggenhime | CFO | Sell | 15,000 | $35.01 | $525,150.00 | |
| 9/15/2016 | Christopher M Griffith | VP | Sell | 1,303 | $33.26 | $43,337.78 | |
| 9/12/2016 | Andrew Guggenhime | CFO | Sell | 10,000 | $32.53 | $325,300.00 | |
| 9/1/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $31.63 | $347,930.00 | |
| 9/1/2016 | William R Ringo | Director | Sell | 500 | $32.00 | $16,000.00 | |
| 8/15/2016 | Christopher M Griffith | VP | Sell | 1,303 | $31.75 | $41,370.25 | |
| 8/11/2016 | Andrew Guggenhime | CFO | Sell | 10,000 | $31.02 | $310,200.00 | |
| 8/1/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $33.18 | $82,950.00 | |
| 8/1/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $33.19 | $365,090.00 | |
| 8/1/2016 | William R Ringo | Director | Sell | 500 | $33.65 | $16,825.00 | |
| 7/15/2016 | Christopher M Griffith | VP | Sell | 1,303 | $30.02 | $39,116.06 | |
| 7/11/2016 | Andrew Guggenhime | CFO | Sell | 10,000 | $30.15 | $301,500.00 | |
| 7/5/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $29.62 | $325,820.00 | |
| 7/1/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $29.48 | $73,700.00 | |
| 6/23/2016 | Luis C Pena | Insider | Sell | 10,000 | $30.01 | $300,100.00 | |
| 6/15/2016 | Luis C Pena | Insider | Sell | 10,000 | $29.47 | $294,700.00 | |
| 6/13/2016 | Christopher M Griffith | VP | Sell | 4,405 | $30.16 | $132,854.80 | |
| 6/1/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $31.65 | $79,125.00 | |
| 6/1/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $31.57 | $347,270.00 | |
| 5/2/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $25.09 | $62,725.00 | |
| 5/2/2016 | Thomas G Wiggans | CEO | Sell | 9,000 | $25.11 | $225,990.00 | |
| 4/1/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $20.84 | $52,100.00 | |
| 4/1/2016 | Thomas G Wiggans | CEO | Sell | 7,000 | $20.69 | $144,830.00 | |
| 3/1/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $22.55 | $56,375.00 | |
| 3/1/2016 | Thomas G Wiggans | CEO | Sell | 7,000 | $22.57 | $157,990.00 | |
| 2/1/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $27.26 | $68,150.00 | |
| 2/1/2016 | Thomas G Wiggans | CEO | Sell | 9,000 | $27.25 | $245,250.00 | |
| 1/4/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $33.17 | $82,925.00 | |
| 1/4/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $33.17 | $364,870.00 | |
| 12/1/2015 | Eugene A Bauer | Insider | Sell | 2,500 | $29.65 | $74,125.00 | |
| 11/2/2015 | Eugene A Bauer | Insider | Sell | 2,500 | $27.82 | $69,550.00 | |
| 10/1/2015 | Eugene A Bauer | Insider | Sell | 2,500 | $22.87 | $57,175.00 | |
| 9/14/2015 | Eugene A Bauer | Insider | Sell | 22,500 | $28.05 | $631,125.00 | |
| 11/25/2014 | Matthew K Fust | Director | Buy | 6,000 | $16.77 | $100,620.00 | |
| 10/8/2014 | Bay City Capital Llc | Director | Buy | 69,112 | $16.00 | $1,105,792.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Dermira (NASDAQ:DERM)
Latest Headlines for Dermira (NASDAQ:DERM)
| Source: |
|
| Date | Headline |
|---|
 | Dermira, Inc. (DERM) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - August 17 at 9:26 PM |
| Dermira, Inc. (DERM) Raised to Sell at BidaskClub
www.americanbankingnews.com - August 16 at 11:32 PM |
| Dermira, Inc. (DERM) Director Fred B. Craves Buys 30,000 Shares
www.americanbankingnews.com - August 14 at 10:46 PM |
 | See what the IHS Markit Score report has to say about Dermira Inc.
finance.yahoo.com - August 14 at 6:11 PM |
| Dermira, Inc. (NASDAQ:DERM) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 11 at 6:18 PM |
| Is Dermira Inc (NASDAQ:DERM)'s Confidence In Lebrikizumab Warranted?
finance.yahoo.com - August 11 at 12:07 AM |
| Leerink Swann Comments on Dermira, Inc.'s Q3 2017 Earnings (NASDAQ:DERM)
www.americanbankingnews.com - August 10 at 12:04 PM |
 | Dermira (DERM) Enters Pact to License Exclusive, Worldwide Rights to Lebrikizumab
www.streetinsider.com - August 9 at 5:58 PM |
 | BRIEF-Dermira enters into agreement to license exclusive, worldwide rights to Lebrikizumab
www.businessinsider.com - August 9 at 5:58 PM |
| Equities Analysts Offer Predictions for Dermira, Inc.'s FY2020 Earnings (DERM)
www.americanbankingnews.com - August 9 at 3:02 PM |
| Dermira Enters into Agreement to License Exclusive, Worldwide Rights to Lebrikizumab
finance.yahoo.com - August 8 at 5:32 PM |
| Dermira, Inc. (DERM) Releases Quarterly Earnings Results
www.americanbankingnews.com - August 8 at 12:46 PM |
 | Dermira Becomes Oversold (DERM)
www.nasdaq.com - August 7 at 6:12 PM |
 | BRIEF-Dermira Q2 qtrly net loss per share $0.93
www.reuters.com - August 7 at 6:12 PM |
| Dermira Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 7 at 6:12 PM |
| Dermira reports 2Q loss
finance.yahoo.com - August 7 at 6:12 PM |
| Dermira, Inc. (NASDAQ:DERM) CEO Sells $13,790.00 in Stock
www.americanbankingnews.com - August 2 at 9:38 PM |
| Dermira, Inc. (NASDAQ:DERM) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - July 28 at 10:27 PM |
| Suffering from excessive perspiration? Don't sweat it, we...
finance.yahoo.com - July 28 at 7:51 PM |
 | UCB and Dermira Announce U.S. and EU Regulatory...
www.benzinga.com - July 25 at 5:49 PM |
| UCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis
finance.yahoo.com - July 25 at 3:34 AM |
| ETFs with exposure to Dermira, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 5:32 PM |
| Dermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : July 21, 2017
finance.yahoo.com - July 21 at 7:35 PM |
| Dermira, Inc. (NASDAQ:DERM) Given Buy Rating at Needham & Company LLC
www.americanbankingnews.com - July 18 at 1:18 PM |
| Dermira, Inc. (NASDAQ:DERM) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - July 17 at 12:33 PM |
| ETFs with exposure to Dermira, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 3:45 PM |
| Dermira, Inc. – Value Analysis (NASDAQ:DERM) : July 12, 2017
finance.yahoo.com - July 12 at 6:28 PM |
| Dermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : July 11, 2017
finance.yahoo.com - July 11 at 6:58 PM |
| Dermira, Inc. (DERM) Insider Sells $75,000.00 in Stock
www.americanbankingnews.com - July 6 at 8:06 PM |
| Insider Selling: Dermira, Inc. (NASDAQ:DERM) CEO Sells 5,000 Shares of Stock
www.americanbankingnews.com - July 5 at 7:45 PM |
| Dermira, Inc. (NASDAQ:DERM) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - July 3 at 3:22 PM |
| Evercore ISI Begins Coverage on Dermira, Inc. (DERM)
www.americanbankingnews.com - June 29 at 6:42 PM |
| Dermira (DERM) Reports Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition
www.streetinsider.com - June 26 at 10:37 PM |
| BRIEF-Dermira says findings from nonclinical studies evaluating mechanism of action for olumacostat glasaretil in sebum inhibition were published
www.reuters.com - June 26 at 10:37 PM |
| Newly Published Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition
finance.yahoo.com - June 26 at 5:34 PM |
| Analysts Offer Predictions for Dermira, Inc.'s FY2017 Earnings (DERM)
www.americanbankingnews.com - June 26 at 7:41 AM |
| Dermira, Inc. (DERM) Now Covered by Cantor Fitzgerald
www.americanbankingnews.com - June 22 at 2:58 PM |
| Dermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : June 22, 2017
finance.yahoo.com - June 22 at 10:24 AM |
| Eugene A. Bauer Sells 2,500 Shares of Dermira, Inc. (DERM) Stock
www.americanbankingnews.com - June 21 at 8:04 PM |
| Dermira, Inc. (DERM) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - June 20 at 10:30 AM |
| Dermira, Inc. (DERM) Raised to Hold at BidaskClub
www.americanbankingnews.com - June 15 at 6:58 PM |
| Thomas G. Wiggans Sells 5,000 Shares of Dermira Inc (DERM) Stock
www.americanbankingnews.com - June 5 at 10:19 PM |
| Dermira to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - May 30 at 4:38 PM |
| Short Interest in Dermira Inc (DERM) Grows By 66.8%
www.americanbankingnews.com - May 28 at 7:02 AM |
| Dermira Inc (DERM) PT Lowered to $40.00
www.americanbankingnews.com - May 27 at 12:58 AM |
| Dermira Inc (DERM) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 26 at 10:50 AM |
| Teva Pharma, Eagle Pharma, Depomed Among Slew Getting Price Haircuts
finance.yahoo.com - May 25 at 6:30 PM |
| Dermira Inc (DERM) Short Interest Up 2.9% in April
www.americanbankingnews.com - May 22 at 9:16 PM |
| DERMIRA, INC. (DERM)
finance.yahoo.com - May 16 at 9:43 PM |
| Insider Selling: Dermira Inc (DERM) SVP Sells 1,312 Shares of Stock
www.americanbankingnews.com - May 16 at 8:44 PM |
Dermira (DERM) Chart for Saturday, August, 19, 2017
